Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Non-Current Deferred Tax Liability (2019 - 2021)

Allogene Therapeutics (ALLO) has disclosed Non-Current Deferred Tax Liability for 2 consecutive years, with $12.8 million as the latest value for Q4 2021.

  • Quarterly Non-Current Deferred Tax Liability changed N/A to $12.8 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $12.8 million through Dec 2021, changed N/A year-over-year, with the annual reading at $12.8 million for FY2021, N/A changed from the prior year.
  • Non-Current Deferred Tax Liability hit $12.8 million in Q4 2021 for Allogene Therapeutics, down from $13.2 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $13.2 million in Q4 2019 to a low of $12.8 million in Q4 2021.